Железодефицитная анемия в практике гастроэнтеролога и хирурга: актуальные аспекты диагностики и лечения

1. Iron deficiency anemia: assessment, prevention, and control. A guide for programme managers. UNICEF, United Nations University, WHO. Geneva: World Health Organization, 2001. https://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/ WHO_NHD_01.3/en/
2. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. Geneva, World Health Organization, 2008. https://apps.who.int/iris/handle/10665/43894
3. WHO. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015. https://www.who.int/nutrition/publications/micronutrients/global_ prevalence_anaemia_2011/en/
4. Серов В.Н., Шаповаленко C.A., Флакс Г.А., Царюк А.В. Диагностика и лечение железодефицитных состояний у женщин в различные периоды жизни. Журн. Российского общества акушеров-гинекологов. 2006; 2. http://ag-info.ru/files/jroag/2006-2/jroag-06-02-15.pdf
[Serov V.N., Shapovalenko C.A., Flaks G.A., Tsariuk A.V. Diagnostika i lechenie zhelezodefitsitnykh sostoianii u zhenshchin v razlichnye periody zhizni. Zhurn. Rossiiskogo obshchestva akusherov-ginekologov. 2006; 2. http://ag-info.ru/files/jroag/2006-2/jroag-06-02-15.pdf (in Russian).]
5. Чилова Р.А., Мурашко А.В., Вечорко В.И. и др. Профилактика и лечение железодефицитных состояний у беременных и кормящих женщин. РМЖ. 2017; 15: 1092–5 https://www.elibrary.ru/item.asp?id=30309172
[Chilova R.A., Murashko A.V., Vechorko V.I. et al. Profilaktika i lechenie zhelezodefitsitnykh sostoianii u beremennykh i kormiashchikh zhenshchin. RMZh. 2017; 15: 1092–5 https://www.elibrary.ru/
item.asp?id=30309172 (in Russian).]
6. Johnson–Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol 2011; 4 (3): 177–84. DOI: 10.1177/1756283X11398736
7. Трухан Д.И. Железодефицитная анемия: актуальные вопросы диагностики и профилактики на этапе оказания первичной медико-санитарной помощи. Фарматека. 2018; 13: 84–90. DOI: 10.18565/pharmateca.2018.13.84-90
[Trukhan D.I. Zhelezodefitsitnaia anemiia: aktual'nye voprosy diagnostiki i profilaktiki na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Farmateka. 2018; 13: 84–90. DOI: 10.18565/pharmateca.2018.13.84-90 (in Russian).]
8. Тарасова И.С. Железодефицитная анемия у детей и подростков. Вопросы современной педиатрии. 2011; 2: 40–8. https://www.elibrary.ru/item.asp?id=16458643
[Tarasova I.S. Zhelezodefitsitnaia anemiia u detei i podrostkov. Voprosy sovremennoi pediatrii. 2011; 2: 40–8. https://www.elibrary.ru/item.asp?id=16458643 (in Russian).]
9. Трухан Д.И., Белкина Л.В., Чусова Н.А. Железодефицитная анемия в практике врача поликлиники: актуальные аспекты диагностики и лечения. Справочник поликлинического врача. 2020; 1: 17–23. https://omnidoctor.ru/library/izdaniya-dlya-vrachey/spravochnik-poliklinicheskogo-vracha/2020/1-2020...
[Trukhan D.I., Belkina L.V., Chusova N.A. Zhelezodefitsitnaia anemiia v praktike vracha polikliniki: aktual'nye aspekty diagnostiki i lecheniia. Handbook for Practitioners Doctors. 2020; 1: 17–23. https://omnidoctor.ru/library/izdaniya-dlya-vrachey/spravochnik-poliklinicheskogo-vracha/2020/1-2020... (in Russian).]
10. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014; 19: 164–74. https://pubmed.ncbi.nlm.nih.gov/24778671/
11. Rockey DC, Altayar O, Falck-Ytter Y, Kalmaz D. AGA Technical Review on Gastrointestinal Evaluation of Iron Deficiency Anemia. American Gastroenterological Association. 2020. DOI: 10.1053/j.gastro.2020.06.045
12. Camaschella C. Iron deficiency. Blood 2019; 133 (1): 30–9. DOI: 10.1182/blood-2018-05-815944
13. Muñoz M., Gómez-Ramírez S., Campos A et al. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus 2015; 13 (3): 370–9. DOI: 10.2450/2015.0014-15
14. Трухан Д.И., Тарасова Л.В. Железодефицитная анемия: актуальные вопросы диагностики, лечения и профилактики. Гинекология. 2013; 5: 95–9. https://www.elibrary.ru/item.asp?id=21027125
[Trukhan D.I., Tarasova L.V. Zhelezodefitsitnaia anemiia: aktual'nye voprosy diagnostiki, lecheniia i profilaktiki. Gynecology. 2013; 5: 95–9. https://www.elibrary.ru/item.asp?id=21027125 (in Russian).]
15. Трухан Д.И., Викторова И.А. Нефрология. Эндокринология. Гематология. СПб.: СпецЛит, 2017. https://fictionbook.ru/author/d_i_truhan/nefrologiya_yendokrinologiya_gematologiya/
[Trukhan D.I., Viktorova I.A. Nephrology. Endocrinology. Hematology. Saint Petersburg: SpetsLit, 2017. https://fictionbook.ru/author/d_i_truhan/nefrologiya_yendokrinologiya_gematologiya/ (in Russian).]
16. Трухан Д.И., Юренев Г.Л., Чусова Н.А. Железодефицитная анемия: актуальные аспекты диагностики и лечения в реальной клинической практике терапевта. Терапия. 2019; 1: 172–81. DOI: 10.18565/therapy.2019.1.172-181
[Trukhan D.I., Iurenev G.L., Chusova N.A. Zhelezodefitsitnaia anemiia: aktual'nye aspekty diagnostiki i lecheniia v real'noi klinicheskoi praktike terapevta. Terapiia. 2019; 1: 172–81. DOI: 10.18565/therapy.2019.1.172-181 (in Russian).]
17. Лузина Е.В., Ларева Н.В. Анемия и заболевания желудочно-кишечного тракта. Терапевтический архив. 2013; 4: 102–5. https://www.elibrary.ru/item.asp?id=19062820
[Luzina E.V., Lareva N.V. Anemiia i zabolevaniia zheludochno-kishechnogo trakta. Therapeutic Archive. 2013; 4: 102–5. https://www.elibrary.ru/item.asp?id=19062820 (in Russian).]
18. Трухан Д.И., Никоненко В.А. Дифференциальный диагноз крови в стуле. Точное обследование – залог успешного лечения. Стационарозамещающие технологии: амбулаторная хирургия. 2016; 3–4 (63–64): 36–43. https://www.elibrary.ru/item.asp?id=27337736
[Trukhan D.I., Nikonenko V.A. Differentsial'nyi diagnoz krovi v stule. Tochnoe obsledovanie – zalog uspeshnogo lecheniia. Statsionarozameshchaiushchie tekhnologii: ambulatornaia khirurgiia. 2016; 3–4 (63–64): 36–43. https://www.elibrary.ru/item.asp?id=27337736 (in Russian).]
19. Трухан Д.И. Кровь в стуле: вопросы дифференциальной диагностики. Справочник поликлинического врача. 2016; 6: 38–42. https://www.elibrary.ru/item.asp?id=29117572
[Trukhan D.I. Krov' v stule: voprosy differentsial'noi diagnostiki. Handbook for Practitioners Doctors. 2016; 6: 38–42. https://www.elibrary.ru/item.asp?id=29117572 (in Russian).]
20. Трухан Д.И., Филимонов С.Н. Дифференциальный диагноз основных гастроэнтерологических синдромов и симптомов. М.: Практическая медицина, 2016. https://lettercan.at.ua/news/differencialnyj_diagnoz_osnovnykh_gastroehnterologicheskikh_sindromov_i...
[Trukhan D.I., Filimonov S.N. Differential diagnosis of major gastroenterological syndromes and symptoms. Moscow: Prakticheskaia meditsina, 2016. https://lettercan.at.ua/news/differencialnyj_diagnoz_osnovnykh_gastroehnterologicheskikh_sindromov_i... (in Russian).]
21. Bull-Henry K, Al-Kawas FH. Evaluation of occult gastrointestinal bleeding. Am Fam Physician 2013; 87 (6): 430–6. https://pubmed.ncbi.nlm.nih.gov/23547576/
22. Peña-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev 2015; 7: CD004736. DOI: 10.1002/14651858.CD004736.pub5
23. Румянцев А.Г., Масчан А.А. Федеральные клинические рекомендации по диагностике и лечению железодефицитной анемии. М., 2014. http://nodgo.org/sites/default/files/ФКР%20по%20диагностике%20и%20лечению%20железодефицитной%20анеми...
[Rumyantsev A.G., Maschan A.A. Federal clinical guidelines for the diagnosis and treatment of iron deficiency anemia. Moscow, 2014. http://nodgo.org/sites/default/files/ФКР%20по%20диагностике%20и%20лечению%20железодефицитной%20анеми... (in Russian).]
24. Румянцев А.Г., Масчан А.А., Чернов В.М., Тарасова И.С. Федеральные клинические рекомендации по диагностике и лечению железодефицитной анемии. М., 2015. http://nodgo.org/sites/default/files/ЖДА%20%28испр.%29.pdf
[Rumyantsev A.G., Maschan A.A., Chernov V.M., Tarasova I.S. Federal clinical guidelines for the diagnosis and treatment of iron deficiency anemia. M., 2015. http://nodgo.org/sites/
default/files/ЖДА%20%28испр.%29.pdf (in Russian).]
25. Aapro M, Osterborg A, Gascon P и др. Распространенность и лечение анемий при онкологических заболеваниях, железодефицит и специфическая роль внутривенных препаратов железа. Новые подходы в онкологии. 2013; 1 (21): 5–16. https://medi.ru/info/11182/
[Aapro M, Osterborg A, Gascon P et al. Rasprostranennost' i lechenie anemii pri onkologicheskikh zabolevaniiakh, zhelezodefitsit i spetsificheskaia rol' vnutrivennykh preparatov zheleza. Novye podkhody v onkologii. 2013; 1 (21): 5–16. https://medi.ru/info/11182/ (in Russian).]
26. Aapro M, Beguin Y, Bokemeyer C et al, ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29 (Suppl. 4): iv271. DOI: 10.1093/annonc/mdy323
27. Muñoz M, Acheson AG, Auerbach M et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72 (2): 233–47. DOI: 10.1111/anae.13773
28. Muñoz M; panel for the international consensus statement on perio-operative management of anaemia iron deficiency. Peri-operative correction of non-anaemic iron deficiency. A reply. Anaesthesia. 2017; 72 (7): 911–2. DOI: 10.1111/anae.13947
29. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9 (3): 211–22. DOI: 10.1093/ecco-jcc/jju009
30. Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68 (Suppl. 3): s1–s106. DOI: 10.1136/gutjnl-2019-318484
31. Martins R, Carmona C, George B, Epstein J; Guideline Committee. Management of Crohn's disease: summary of updated NICE guidance. BMJ 2019; 367: l5940. DOI: 10.1136/bmj.l5940
32. Lightner AL, Vogel JD, Carmichael JC et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum 2020; 63 (8): 1028–52. DOI: 10.1097/DCR.0000000000001716
33. Клинические рекомендации. Колопроктология. Под ред. Ю.А. Шелыгина. М.: ГЭОТАР-Медиа, 2015. https://www.gastroscan.ru/literature/authors/9495
[Clinical guidelines. Coloproctology. Ed. Yu.A. Shelygin. Moscow: GEOTAR-Media, 2015. https: //www.gastroscan.ru/literature/authors/9495 (in Russian).]
34. Клинические рекомендации. Колопроктология. Под ред. Ю.А. Шелыгина. М.: ГЭОТАР-Медиа, 2017. https://search.rsl.ru/ru/record/01009375363
[Clinical guidelines. Coloproctology. Ed. Yu.A. Shelygin. Moscow: GEOTAR-Media, 2017. https://search.rsl.ru/ru/record/01009375363 (in Russian).]
35. Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению болезни Крона. Колопроктология. 2017; 2: 7–29. https://www.elibrary.ru/
item.asp?id=29145096
[Ivashkin V.T., Shelygin Iu.A., Khalif I.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniiu bolezni Krona. Koloproktologiia. 2017; 2: 7–29. https://www.elibrary.ru/item.asp?id=29145096 (in Russian).]
36. Ивашкин В.Т., Шелыгин Ю.А., Абдулганиева Д.И. и др. Клинические рекомендации по диагностике и лечению болезни Крона у взрослых (Проект). Колопроктология. 2020; 2: 8–38. DOI: 10.33878/2073-7556-2020-19-2-8-38
[Ivashkin V.T., Shelygin Iu.A., Abdulganieva D.I. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu bolezni Krona u vzroslykh (Proekt). Koloproktologiia. 2020; 2: 8–38. DOI: 10.33878/2073-7556-2020-19-2-8-38 (in Russian).]
37. Goodnough LT. Blood management: transfusion medicine comes of age. Lancet 2013; 381 (9880): 1791–2. DOI: 10.1016/S0140-6736(13)60673-X
38. Чемоданов И.Г., Камельских Д.В., Шестаков Е.А. и др. Знания и практика менеджмента крови пациента. Трансфузиология. 2019; 2: 4–22. https://www.elibrary.ru/item.asp?id=43613987
[Chemodanov I.G., Kamel'skikh D.V., Shestakov E.A. et al. Znaniia i praktika menedzhmenta krovi patsienta. Transfuziologiia. 2019; 2: 4–22. https://www.elibrary.ru/item.asp?id=43613987 (in Russian).]
39. Жибурт Е.Б. Менеджмент крови пациента при критическом кровотечении. Эффективная фармакотерапия. 2014; 6: 20–6. https://www.elibrary.ru/item.asp?id=22593180
[Zhiburt E.B. Menedzhment krovi patsienta pri kriticheskom krovotechenii. Effektivnaia farmakoterapiia. 2014; 6: 20–6. https://www.elibrary.ru/item.asp?id=22593180 (in Russian).]
40. Жибурт Е.Б. Менеджмент крови пациента. Здравоохранение. 2014; 4: 58–67. https://www.elibrary.ru/item.asp?id=21303062
[Zhiburt E.B. Menedzhment krovi patsienta. Zdravookhranenie. 2014; 4: 58–67. https://www.elibrary.ru/item.asp?id=21303062 (in Russian).]
41. Mace TA, Syed A, Bhandari S. Iron (III) isomaltoside 1000. Expert Rev Hematol 2013; 6 (3): 239–46. DOI: 10.1586/ehm.13.15
42. Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther 2012; 6: 43–51. DOI: 10.2147/DDDT.S30015
43. Kalra PA. Introducing iron isomaltoside 1000 (MonoferR)-development rationale and clinical experience. NDT Plus 2011; 4 (Suppl. 1): i10–i13. DOI: 10.1093/ndtplus/sfr042
44. Bhandari S. Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care. NDT Plus 2011; 4 (Suppl. 1): i14–i19. DOI: 10.1093/ndtplus/sfr044
45. Jahn MR, Andreasen HB, Fütterer S et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78 (3): 480–91. DOI: 10.1016/j.ejpb.2011.03.016
46. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (MonoferR) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis 2016; 9: 53–64. DOI: 10.2147/IJNRD.S89704.
47. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (MonoferR) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 2015; 109 (3): 257–66. DOI: 10.1111/vox.12278
48. Birgegård G, Henry D, Glaspy J et al. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy 2016; 36 (4): 402–14. DOI: 10.1002/phar.1729
49. Reinisch W, Staun M, Tandon RK et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108 (12): 1877–88. DOI: 10.1038/ajg.2013.335
50. Reinisch W, Altorjay I, Zsigmond F et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol 2015; 50 (10): 1226–33. DOI: 10.3109/00365521.2015.1031168
51. Dahlerup JF, Jacobsen BA, van der Woude J et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol 2016; 51 (11): 1332–8. DOI: 10.1080/00365521.2016.1196496
52. Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv 2017; 14 (12): 1439–46. DOI: 10.1080/17425247.2017.1393412
53. Stein J, Walper A, Klemm W et al. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scand J Gastroenterol 2018; 53 (9): 1059–65. DOI: 10.1080/00365521.2018.1498914
54. Pollock RF, Muduma G. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Adv Ther 2018; 35 (12): 2128–37. DOI: 10.1007/s12325-018-0827-5
55. Detlie TE, Lindstrøm JC, Jahnsen ME et al. ncidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther 2019; 50 (4): 397–406. DOI: 10.1111/apt.15386
56. Derman R, Roman E, Smith-Nguyen GN et al. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia. Am J Hematol 2018; 93 (6): E148–E150. DOI: 10.1002/ajh.25094
57. Holm C. Intravenous iron treatment in the puerperium. Dan Med J 2018; 65 (4): B5471. https://pubmed.ncbi.nlm.nih.gov/29619936/
58. Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med 2019; 32 (17): 2797–804. DOI: 10.1080/14767058.2018
59. Wikström B, Bhandari S, Barany P et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol 2011; 24 (5): 589–96. DOI: 10.5301/JN.2011.6248
60. Bhandari S, Kalra PA, Kothari J et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant 2015; 30 (9): 1577–89. DOI: 10.1093/ndt/gfv096
61. Biggar P, Leistikow F, Walper A. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia Clin Nephrol 2016; 86 (12): 310–8. DOI: 10.5414/CN108941
62. Kalra PA, Bhandari S, Saxena S et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016; 31 (4): 646–55. DOI: 10.1093/ndt/gfv293
63. Jensen G, Gøransson LG, Fernström A et al. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia). Clin Nephrol 2019; 91 (4): 246–53. DOI: 10.5414/CN109474
64. Bhandari S, Kalra PA, Berkowitz M et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant 2020: gfaa011. DOI: 10.1093/ndt/gfaa011
65. Achebe MM, Glaspy J, Kalra PA et al. A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial. Am J Hematol 2020. DOI: 10.1002/ajh.25920
66. Садыгова Г.Г. Анемии при воспалительных заболеваниях кишечника (обзор литературы). Колопроктология. 2016; 3 (57): 84–90. https://elibrary.ru/item.asp?id=26569563
[Sadygova G.G. Anemii pri vospalitel'nykh zabolevaniiakh kishechnika (obzor literatury). Koloproktologiia. 2016; 3 (57): 84–90. https://elibrary.ru/item.asp?id=26569563 (in Russian).]
67. Губонина И.В., Щукина О.Б., Стуклов Н.И. и др. Анемия при воспалительных заболеваниях кишечника: подходы к диагностике, лечению и профилактике. Альманах клинической медицины. 2019; 8: 721–32. DOI: 10.18786/2072-0505-2019-47-078
[Gubonina I.V., Shchukina O.B., Stuklov N.I. et al. Anemiia pri vospalitel'nykh zabolevaniiakh kishechnika: podkhody k diagnostike, lecheniiu i profilaktike. Al'manakh klinicheskoi meditsiny. 2019; 8: 721–32. DOI: 10.18786/2072-0505-2019-47-078 (in Russian).]
68. Абашин С.Ю. Железодефицит у женщин и возможности его коррекции. Онкогинекология. 2015; 1: 63–9. https://elibrary.ru/item.asp?id=25460951
[Abashin S.Iu. Zhelezodefitsit u zhenshchin i vozmozhnosti ego korrektsii. Onkoginekologiia. 2015; 1: 63–9. https://elibrary.ru/item.asp?id=25460951 (in Russian).]
69. Хашукоева А.З., Агаева М.И., Дугиева М.З. и др. Современные подходы к лечению железодефицитной анемии у больных с гинекологической патологией. Лечащий врач. 2017; 12: 23–7. https://elibrary.ru/item.asp?id=32332991
[Khashukoeva A.Z., Agaeva M.I., Dugieva M.Z. et al. Sovremennye podkhody k lecheniiu zhelezodefitsitnoi anemii u bol'nykh s ginekologicheskoi patologiei. Lechashchii vrach. 2017; 12: 23–7. https://elibrary.ru/item.asp?id=32332991 (in Russian).]
70. Озолиня Л.А., Керчелаева С.Б., Раздобреев И.А. Современные методы эффективной коррекции железодефицитной анемии в послеродовом периоде. Мед. совет. 2017; 13: 26–32. DOI: 10.21518/2079-701X-2017-13-26-32
[Ozolinia L.A., Kerchelaeva S.B., Razdobreev I.A. Sovremennye metody effektivnoi korrektsii zhelezodefitsitnoi anemii v poslerodovom periode. Med. sovet. 2017; 13: 26–32. DOI: 10.21518/2079-701X-2017-13-26-32 (in Russian).]
71. Озолиня Л.А., Керчелаева С.Б. Применение внутривенного введения препарата железа (III) гидроксид олигоизомальтозата для лечения анемии в послеродовом периоде. Вестн. последипломного медицинского образования. 2017; 4: 10–6. https://elibrary.ru/item.asp?id=30635169
[Ozolinia L.A., Kerchelaeva S.B. Primenenie vnutrivennogo vvedeniia preparata zheleza (III) gidroksid oligoizomal'tozata dlia lecheniia anemii v poslerodovom periode. Vestn. poslediplomnogo meditsinskogo obrazovaniia. 2017; 4: 10–6. https://elibrary.ru/item.asp?id=30635169 (in Russian).]
72. Атаджанян А.С. Анемия у беременных: клинико-патогенетические подходы к ведению беременности. Журн. акушерства и женских болезней. 2017; 5: 56–63. DOI: 10.17816/JOWD66556-63
[Atadzhanian A.S. Anemiia u beremennykh: kliniko-patogeneticheskie podkhody k vedeniiu beremennosti. Zhurn. akusherstva i zhenskikh boleznei. 2017; 5: 56–63. DOI: 10.17816/JOWD66556-63 (in Russian).]
73. Обухова О.А., Курмуков И.А., Кашия Ш.Р. Диагностика и лечение железодефицитной анемии в онкологии. Онкогинекология. 2014; 2: 67–76. https://elibrary.ru/item.asp?id=22590405
[Obukhova O.A., Kurmukov I.A., Kashiia Sh.R. Diagnostika i lechenie zhelezodefitsitnoi anemii v onkologii. Onkoginekologiia. 2014; 2: 67–76. https://elibrary.ru/item.asp?id=22590405 (in Russian).]
74. Костюченко Л.Н., Михайлянц Г.С., Данилов М.Ю. и др. Железодефицитные синдромы в клинической онкологии и их коррекция препаратами нутритивного действия. Мед. алфавит. 2019; 13 (388): 20–5. DOI: 10.33667/2078-5631-2019-2-13(388)-20-25
[Kostiuchenko L.N., Mikhailiants G.S., Danilov M.Iu. et al. Zhelezodefitsitnye sindromy v klinicheskoi onkologii i ikh korrektsiia preparatami nutritivnogo deistviia. Med. alfavit. 2019; 13 (388): 20–5. DOI: 10.33667/2078-5631-2019-2-13(388)-20-25 (in Russian).]
75. Костюченко Л.Н., Михайлянц Г.С., Данилов М.А. и др. Ранняя нутриционная реабилитация гериатрических больных колоректальным раком, сопровождающимся железодефицитными синдромамина фоне химиотерапии. Клин. геронтология. 2020; 1–2: 16–21. DOI: 10.26347/1607-2499202001-02016-021
[Kostiuchenko L.N., Mikhailiants G.S., Danilov M.A. et al. Ranniaia nutritsionnaia reabilitatsiia geriatricheskikh bol'nykh kolorektal'nym rakom, soprovozhdaiushchimsia zhelezodefitsitnymi sindromamina fone khimioterapii. Klin. gerontologiia. 2020; 1–2: 16–21. DOI: 10.26347/1607-2499202001-02016-021 (in Russian).]
76. Богданов А.Н., Щербак С.Г., Павлович Д. Анемии в гериатрической практике: история и современность. Вестн. гематологии. 2018; 3: 37–43. https://elibrary.ru/item.asp?id=42736732
[Bogdanov A.N., Shcherbak S.G., Pavlovich D. Anemii v geriatricheskoi praktike: istoriia i sovremennost'. Vestn. gematologii. 2018; 3: 37–43. https://elibrary.ru/item.asp?id=42736732 (in Russian).]
77. Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2019 год. http://static.government.ru/media/files/8qGPVaoQtztDoiEqNojWTre2bB8QtV6w.pdf [(in Russian).]
78. Wolf M, Rubin J, Achebe M et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA 2020; 323 (5): 432–43. DOI: 10.1001/jama.2019.22450
79. Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. Transfusion 2018; 58 (4): 974–81. DOI: 10.1111/trf.14521
80. Sivakumar C, Jubb VM, Lamplugh A, Bhandari S. Safety of Intravenous Iron – Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients. Perit Dial Int 2019; 39 (2): 192–5. DOI: 10.3747/pdi.2018.00125
81. Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol 2020; 13 (2): 187–95. DOI: 10.1080/17474086.2020.1709437
82. Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol 2019; 12 (2): 129–36. DOI: 10.1080/17474086.2019.1575202
83. Auerbach M, Henry D, Derman RJ et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol 2019; 94 (9): 1007–14. DOI: 10.1002/ajh.25564
84. Derman R, Roman E, Modiano MR et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol 2017; 92 (3): 286–91. DOI: 10.1002/ajh.24633
85. Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag 2011; 7: 103–13. DOI: 10.2147/TCRM.S17536
86. Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.Clinicoecon Outcomes Res 2017; 9: 475–83. DOI: 10.2147/CEOR.S139525
87. Куликов А.Ю., Скрипник А.Р. Фармакоэкономический анализ лекарственного препарата монофер (железа III – гидроксид олигоизомальтозат) в лечении железодефицитной анемии. Фармакоэкономика: теория и практика. 2016; 1: 183–7. https://elibrary.ru/item.asp?id=25782728
[Kulikov A.Iu., Skripnik A.R. Farmakoekonomicheskii analiz lekarstvennogo preparata monofer (zheleza III – gidroksid oligoizomal'tozat) v lechenii zhelezodefitsitnoi anemii. Farmakoekonomika: teoriia i praktika. 2016; 1: 183–7. https://elibrary.ru/item.asp?id=25782728 (in Russian).]

________________________________________________

1. Iron deficiency anemia: assessment, prevention, and control. A guide for programme managers. UNICEF, United Nations University, WHO. Geneva: World Health Organization, 2001. https://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/ WHO_NHD_01.3/en/
2. Worldwide prevalence of anaemia 1993–2005: WHO global database on anaemia. Geneva, World Health Organization, 2008. https://apps.who.int/iris/handle/10665/43894
3. WHO. The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015. https://www.who.int/nutrition/publications/micronutrients/global_ prevalence_anaemia_2011/en/
4. Serov V.N., Shapovalenko C.A., Flaks G.A., Tsariuk A.V. Diagnostika i lechenie zhelezodefitsitnykh sostoianii u zhenshchin v razlichnye periody zhizni. Zhurn. Rossiiskogo obshchestva akusherov-ginekologov. 2006; 2. http://ag-info.ru/files/jroag/2006-2/jroag-06-02-15.pdf (in Russian).
5. Chilova R.A., Murashko A.V., Vechorko V.I. et al. Profilaktika i lechenie zhelezodefitsitnykh sostoianii u beremennykh i kormiashchikh zhenshchin. RMZh. 2017; 15: 1092–5 https://www.elibrary.ru/item.asp?id=30309172 (in Russian).
6. Johnson–Wimbley TD, Graham DY. Diagnosis and management of iron deficiency anemia in the 21st century. Therap Adv Gastroenterol 2011; 4 (3): 177–84. DOI: 10.1177/1756283X11398736
7. Trukhan D.I. Zhelezodefitsitnaia anemiia: aktual'nye voprosy diagnostiki i profilaktiki na etape okazaniia pervichnoi mediko-sanitarnoi pomoshchi. Farmateka. 2018; 13: 84–90. DOI: 10.18565/pharmateca.2018.13.84-90 (in Russian).
8. Tarasova I.S. Zhelezodefitsitnaia anemiia u detei i podrostkov. Voprosy sovremennoi pediatrii. 2011; 2: 40–8. https://www.elibrary.ru/item.asp?id=16458643 (in Russian).
9. Trukhan D.I., Belkina L.V., Chusova N.A. Zhelezodefitsitnaia anemiia v praktike vracha polikliniki: aktual'nye aspekty diagnostiki i lecheniia. Handbook for Practitioners Doctors. 2020; 1: 17–23. https://omnidoctor.ru/library/izdaniya-dlya-vrachey/spravochnik-poliklinicheskogo-vracha/2020/1-2020... (in Russian).
10. Abbaspour N, Hurrell R, Kelishadi R. Review on iron and its importance for human health. J Res Med Sci 2014; 19: 164–74. https://pubmed.ncbi.nlm.nih.gov/24778671/
11. Rockey DC, Altayar O, Falck-Ytter Y, Kalmaz D. AGA Technical Review on Gastrointestinal Evaluation of Iron Deficiency Anemia. American Gastroenterological Association. 2020. DOI: 10.1053/j.gastro.2020.06.045
12. Camaschella C. Iron deficiency. Blood 2019; 133 (1): 30–9. DOI: 10.1182/blood-2018-05-815944
13. Muñoz M., Gómez-Ramírez S., Campos A et al. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus 2015; 13 (3): 370–9. DOI: 10.2450/2015.0014-15
14. Trukhan D.I., Tarasova L.V. Zhelezodefitsitnaia anemiia: aktual'nye voprosy diagnostiki, lecheniia i profilaktiki. Gynecology. 2013; 5: 95–9. 
https://www.elibrary.ru/item.asp?id=21027125 (in Russian).
15. Trukhan D.I., Viktorova I.A. Nephrology. Endocrinology. Hematology. Saint Petersburg: SpetsLit, 2017. 
https://fictionbook.ru/author/d_i_truhan/nefrologiya_yendokrinologiya_gematologiya/ (in Russian).
16. Trukhan D.I., Iurenev G.L., Chusova N.A. Zhelezodefitsitnaia anemiia: aktual'nye aspekty diagnostiki i lecheniia v real'noi klinicheskoi praktike terapevta. Terapiia. 2019; 1: 172–81. DOI: 10.18565/therapy.2019.1.172-181 (in Russian).
17. Luzina E.V., Lareva N.V. Anemiia i zabolevaniia zheludochno-kishechnogo trakta. Therapeutic Archive. 2013; 4: 102–5. https://www.elibrary.ru/item.asp?id=19062820 (in Russian).
18. Trukhan D.I., Nikonenko V.A. Differentsial'nyi diagnoz krovi v stule. Tochnoe obsledovanie – zalog uspeshnogo lecheniia. Statsionarozameshchaiushchie tekhnologii: ambulatornaia khirurgiia. 2016; 3–4 (63–64): 36–43. https://www.elibrary.ru/item.asp?id=27337736 (in Russian).
19. Trukhan D.I. Krov' v stule: voprosy differentsial'noi diagnostiki. Handbook for Practitioners Doctors. 2016; 6: 38–42. https://www.elibrary.ru/item.asp?id=29117572 (in Russian).
20. Trukhan D.I., Filimonov S.N. Differential diagnosis of major gastroenterological syndromes and symptoms. Moscow: Prakticheskaia meditsina, 2016. https://lettercan.at.ua/news/differencialnyj_diagnoz_osnovnykh_gastroehnterologicheskikh_sindromov_i... (in Russian).
21. Bull-Henry K, Al-Kawas FH. Evaluation of occult gastrointestinal bleeding. Am Fam Physician 2013; 87 (6): 430–6. https://pubmed.ncbi.nlm.nih.gov/23547576/
22. Peña-Rosas JP, De-Regil LM, Garcia-Casal MN, Dowswell T. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev 2015; 7: CD004736. DOI: 10.1002/14651858.CD004736.pub5
23. Rumyantsev A.G., Maschan A.A. Federal clinical guidelines for the diagnosis and treatment of iron deficiency anemia. Moscow, 2014. http://nodgo.org/sites/default/files/ФКР%20по%20диагностике%20и%20лечению%20железодефицитной%20анеми... (in Russian).
24. Rumyantsev A.G., Maschan A.A., Chernov V.M., Tarasova I.S. Federal clinical guidelines for the diagnosis and treatment of iron deficiency anemia. M., 2015. http://nodgo.org/sites/default/files/ЖДА%20%28испр.%29.pdf (in Russian).
25. Aapro M, Osterborg A, Gascon P et al. Rasprostranennost' i lechenie anemii pri onkologicheskikh zabolevaniiakh, zhelezodefitsit i spetsificheskaia rol' vnutrivennykh preparatov zheleza. Novye podkhody v onkologii. 2013; 1 (21): 5–16. 
https://medi.ru/info/11182/ (in Russian).
26. Aapro M, Beguin Y, Bokemeyer C et al, ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2018; 29 (Suppl. 4): iv271. DOI: 10.1093/annonc/mdy323
27. Muñoz M, Acheson AG, Auerbach M et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72 (2): 233–47. DOI: 10.1111/anae.13773
28. Muñoz M; panel for the international consensus statement on perio-operative management of anaemia iron deficiency. Peri-operative correction of non-anaemic iron deficiency. A reply. Anaesthesia. 2017; 72 (7): 911–2. DOI: 10.1111/anae.13947
29. Dignass AU, Gasche C, Bettenworth D et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9 (3): 211–22. DOI: 10.1093/ecco-jcc/jju009
30. Lamb CA, Kennedy NA, Raine T et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68 (Suppl. 3): s1–s106. DOI: 10.1136/gutjnl-2019-318484
31. Martins R, Carmona C, George B, Epstein J; Guideline Committee. Management of Crohn's disease: summary of updated NICE guidance. BMJ 2019; 367: l5940. DOI: 10.1136/bmj.l5940
32. Lightner AL, Vogel JD, Carmichael JC et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum 2020; 63 (8): 1028–52. DOI: 10.1097/DCR.0000000000001716
33. Clinical guidelines. Coloproctology. Ed. Yu.A. Shelygin. Moscow: GEOTAR-Media, 2015. https: //www.gastroscan.ru/literature/authors/9495 (in Russian).
34. Clinical guidelines. Coloproctology. Ed. Yu.A. Shelygin. Moscow: GEOTAR-Media, 2017. https://search.rsl.ru/ru/record/01009375363 (in Russian).
35. Ivashkin V.T., Shelygin Iu.A., Khalif I.L. et al. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniiu bolezni Krona. Koloproktologiia. 2017; 2: 7–29. https://www.elibrary.ru/item.asp?id=29145096 (in Russian).
36. Ivashkin V.T., Shelygin Iu.A., Abdulganieva D.I. et al. Klinicheskie rekomendatsii po diagnostike i lecheniiu bolezni Krona u vzroslykh (Proekt). Koloproktologiia. 2020; 2: 8–38. DOI: 10.33878/2073-7556-2020-19-2-8-38 (in Russian).
37. Goodnough LT. Blood management: transfusion medicine comes of age. Lancet 2013; 381 (9880): 1791–2. DOI: 10.1016/S0140-6736(13)60673-X
38. Chemodanov I.G., Kamel'skikh D.V., Shestakov E.A. et al. Znaniia i praktika menedzhmenta krovi patsienta. Transfuziologiia. 2019; 2: 4–22. 
https://www.elibrary.ru/item.asp?id=43613987 (in Russian).
39. Zhiburt E.B. Menedzhment krovi patsienta pri kriticheskom krovotechenii. Effektivnaia farmakoterapiia. 2014; 6: 20–6. https://www.elibrary.ru/item.asp?id=22593180 (in Russian).
40. Zhiburt E.B. Menedzhment krovi patsienta. Zdravookhranenie. 2014; 4: 58–67. https://www.elibrary.ru/item.asp?id=21303062 (in Russian).
41. Mace TA, Syed A, Bhandari S. Iron (III) isomaltoside 1000. Expert Rev Hematol 2013; 6 (3): 239–46. DOI: 10.1586/ehm.13.15
42. Nordfjeld K, Andreasen H, Thomsen LL. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease. Drug Des Devel Ther 2012; 6: 43–51. DOI: 10.2147/DDDT.S30015
43. Kalra PA. Introducing iron isomaltoside 1000 (MonoferR)-development rationale and clinical experience. NDT Plus 2011; 4 (Suppl. 1): i10–i13. DOI: 10.1093/ndtplus/sfr042
44. Bhandari S. Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care. NDT Plus 2011; 4 (Suppl. 1): i14–i19. DOI: 10.1093/ndtplus/sfr044
45. Jahn MR, Andreasen HB, Fütterer S et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78 (3): 480–91. DOI: 10.1016/j.ejpb.2011.03.016
46. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (MonoferR) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis 2016; 9: 53–64. DOI: 10.2147/IJNRD.S89704.
47. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (MonoferR) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 2015; 109 (3): 257–66. DOI: 10.1111/vox.12278
48. Birgegård G, Henry D, Glaspy J et al. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy 2016; 36 (4): 402–14. DOI: 10.1002/phar.1729
49. Reinisch W, Staun M, Tandon RK et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013; 108 (12): 1877–88. DOI: 10.1038/ajg.2013.335
50. Reinisch W, Altorjay I, Zsigmond F et al. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol 2015; 50 (10): 1226–33. DOI: 10.3109/00365521.2015.1031168
51. Dahlerup JF, Jacobsen BA, van der Woude J et al. High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23. Scand J Gastroenterol 2016; 51 (11): 1332–8. DOI: 10.1080/00365521.2016.1196496
52. Pollock RF, Muduma G. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opin Drug Deliv 2017; 14 (12): 1439–46. DOI: 10.1080/17425247.2017.1393412
53. Stein J, Walper A, Klemm W et al. Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scand J Gastroenterol 2018; 53 (9): 1059–65. DOI: 10.1080/00365521.2018.1498914
54. Pollock RF, Muduma G. An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Adv Ther 2018; 35 (12): 2128–37. DOI: 10.1007/s12325-018-0827-5
55. Detlie TE, Lindstrøm JC, Jahnsen ME et al. ncidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside. Aliment Pharmacol Ther 2019; 50 (4): 397–406. DOI: 10.1111/apt.15386
56. Derman R, Roman E, Smith-Nguyen GN et al. Iron isomaltoside is superior to iron sucrose in increasing hemoglobin in gynecological patients with iron deficiency anemia. Am J Hematol 2018; 93 (6): E148–E150. DOI: 10.1002/ajh.25094
57. Holm C. Intravenous iron treatment in the puerperium. Dan Med J 2018; 65 (4): B5471. https://pubmed.ncbi.nlm.nih.gov/29619936/
58. Holm C, Thomsen LL, Langhoff-Roos J. Intravenous iron isomaltoside treatment of women suffering from severe fatigue after postpartum hemorrhage. J Matern Fetal Neonatal Med 2019; 32 (17): 2797–804. DOI: 10.1080/14767058.2018
59. Wikström B, Bhandari S, Barany P et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol 2011; 24 (5): 589–96. DOI: 10.5301/JN.2011.6248
60. Bhandari S, Kalra PA, Kothari J et al. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant 2015; 30 (9): 1577–89. DOI: 10.1093/ndt/gfv096
61. Biggar P, Leistikow F, Walper A. A prospective observational study of effectiveness and safety of iron isomaltoside in patients with chronic renal failure and iron deficiency anemia Clin Nephrol 2016; 86 (12): 310–8. DOI: 10.5414/CN108941
62. Kalra PA, Bhandari S, Saxena S et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016; 31 (4): 646–55. DOI: 10.1093/ndt/gfv293
63. Jensen G, Gøransson LG, Fernström A et al. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia). Clin Nephrol 2019; 91 (4): 246–53. DOI: 10.5414/CN109474
64. Bhandari S, Kalra PA, Berkowitz M et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant 2020: gfaa011. DOI: 10.1093/ndt/gfaa011
65. Achebe MM, Glaspy J, Kalra PA et al. A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial. Am J Hematol 2020. DOI: 10.1002/ajh.25920
66. Sadygova G.G. Anemii pri vospalitel'nykh zabolevaniiakh kishechnika (obzor literatury). Koloproktologiia. 2016; 3 (57): 84–90. https://elibrary.ru/item.asp?id=26569563 (in Russian).
67. Gubonina I.V., Shchukina O.B., Stuklov N.I. et al. Anemiia pri vospalitel'nykh zabolevaniiakh kishechnika: podkhody k diagnostike, lecheniiu i profilaktike. Al'manakh klinicheskoi meditsiny. 2019; 8: 721–32. DOI: 10.18786/2072-0505-2019-47-078 (in Russian).
68. Abashin S.Iu. Zhelezodefitsit u zhenshchin i vozmozhnosti ego korrektsii. Onkoginekologiia. 2015; 1: 63–9. https://elibrary.ru/item.asp?id=25460951 (in Russian).
69. Khashukoeva A.Z., Agaeva M.I., Dugieva M.Z. et al. Sovremennye podkhody k lecheniiu zhelezodefitsitnoi anemii u bol'nykh s ginekologicheskoi patologiei. Lechashchii vrach. 2017; 12: 23–7. https://elibrary.ru/item.asp?id=32332991 (in Russian).]
70. Ozolinia L.A., Kerchelaeva S.B., Razdobreev I.A. Sovremennye metody effektivnoi korrektsii zhelezodefitsitnoi anemii v poslerodovom periode. Med. sovet. 2017; 13: 26–32. DOI: 10.21518/2079-701X-2017-13-26-32 (in Russian).
71. Ozolinia L.A., Kerchelaeva S.B. Primenenie vnutrivennogo vvedeniia preparata zheleza (III) gidroksid oligoizomal'tozata dlia lecheniia anemii v poslerodovom periode. Vestn. poslediplomnogo meditsinskogo obrazovaniia. 2017; 4: 10–6. 
https://elibrary.ru/item.asp?id=30635169 (in Russian).
72. Atadzhanian A.S. Anemiia u beremennykh: kliniko-patogeneticheskie podkhody k vedeniiu beremennosti. Zhurn. akusherstva i zhenskikh boleznei. 2017; 5: 56–63. DOI: 10.17816/JOWD66556-63 (in Russian).
73. Obukhova O.A., Kurmukov I.A., Kashiia Sh.R. Diagnostika i lechenie zhelezodefitsitnoi anemii v onkologii. Onkoginekologiia. 2014; 2: 67–76.
https://elibrary.ru/item.asp?id=22590405 (in Russian).
74. Kostiuchenko L.N., Mikhailiants G.S., Danilov M.Iu. et al. Zhelezodefitsitnye sindromy v klinicheskoi onkologii i ikh korrektsiia preparatami nutritivnogo deistviia. Med. alfavit. 2019; 13 (388): 20–5. DOI: 10.33667/2078-5631-2019-2-13(388)-20-25 (in Russian).
75. Kostiuchenko L.N., Mikhailiants G.S., Danilov M.A. et al. Ranniaia nutritsionnaia reabilitatsiia geriatricheskikh bol'nykh kolorektal'nym rakom, soprovozhdaiushchimsia zhelezodefitsitnymi sindromamina fone khimioterapii. Klin. gerontologiia. 2020; 1–2: 16–21. DOI: 10.26347/1607-2499202001-02016-021 (in Russian).
76. Bogdanov A.N., Shcherbak S.G., Pavlovich D. Anemii v geriatricheskoi praktike: istoriia i sovremennost'. Vestn. gematologii. 2018; 3: 37–43. https://elibrary.ru/item.asp?id=42736732 (in Russian).
77. Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2019 год. 
http://static.government.ru/media/files/8qGPVaoQtztDoiEqNojWTre2bB8QtV6w.pdf [(in Russian).]
78. Wolf M, Rubin J, Achebe M et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA 2020; 323 (5): 432–43. DOI: 10.1001/jama.2019.22450
79. Gybel-Brask M, Seeberg J, Thomsen LL, Johansson PI. Intravenous iron isomaltoside improves hemoglobin concentration and iron stores in female iron-deficient blood donors: a randomized double-blind placebo-controlled clinical trial. Transfusion 2018; 58 (4): 974–81. DOI: 10.1111/trf.14521
80. Sivakumar C, Jubb VM, Lamplugh A, Bhandari S. Safety of Intravenous Iron – Cosmofer and Monofer Therapy in Peritoneal Dialysis and Non-Dialysis-Dependent Chronic Kidney Disease Patients. Perit Dial Int 2019; 39 (2): 192–5. DOI: 10.3747/pdi.2018.00125
81. Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol 2020; 13 (2): 187–95. DOI: 10.1080/17474086.2020.1709437
82. Pollock RF, Muduma G. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Rev Hematol 2019; 12 (2): 129–36. DOI: 10.1080/17474086.2019.1575202
83. Auerbach M, Henry D, Derman RJ et al. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol 2019; 94 (9): 1007–14. DOI: 10.1002/ajh.25564
84. Derman R, Roman E, Modiano MR et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol 2017; 92 (3): 286–91. DOI: 10.1002/ajh.24633
85. Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag 2011; 7: 103–13. DOI: 10.2147/TCRM.S17536
86. Pollock RF, Muduma G. A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000.Clinicoecon Outcomes Res 2017; 9: 475–83. DOI: 10.2147/CEOR.S139525
87. Kulikov A.Iu., Skripnik A.R. Farmakoekonomicheskii analiz lekarstvennogo preparata monofer (zheleza III – gidroksid oligoizomal'tozat) v lechenii zhelezodefitsitnoi anemii. Farmakoekonomika: teoriia i praktika. 2016; 1: 183–7. https://elibrary.ru/item.asp?id=25782728 (in Russian).

Д.И. Трухан*1, Е.Н. Деговцов1, В.А. Никоненко2, Д.В. Самойлов2

1 ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия;
2 БУЗОО «Областная клиническая больница», Омск, Россия
*dmitry_trukhan@mail.ru

________________________________________________

Dmitry I. Trukhan*1, Evgeny N. Degovtsov1, Vladimir A. Nikonenko2, Dmitry V. Samoilov2

1 Omsk State Medical University, Omsk, Russia;
2 Omsk Regional Hospital, Omsk, Russia
*dmitry_trukhan@mail.ru